Survival Differences in High-Risk Prostate Cancer by Age

被引:0
|
作者
Garcia-Fuentes, Clara [1 ]
Guijarro, Ana [1 ]
Hernandez, Virginia [1 ]
Gonzalo-Balbas, Alvaro [1 ]
Jimenez-Alcaide, Estibaliz [1 ,3 ]
de la Pena, Enrique [1 ]
Perez-Fernandez, Elia [2 ]
Llorente, Carlos [1 ]
机构
[1] Hosp Univ Fdn Alcorcon, Dept Urol, Madrid, Spain
[2] Hosp Univ Fdn Alcorcon, Res Unit, Madrid, Spain
[3] Hosp Univ Fdn Alcorcon, Dept Urol, Avda Budapest 1, Alcorcon 28922, Madrid, Spain
关键词
high-risk prostate cancer; age groups; survival differences; LONG-TERM SURVIVAL; RADICAL PROSTATECTOMY; RADIATION-THERAPY; MEN; COMORBIDITY; RADIOTHERAPY; IMPACT; DEATH;
D O I
10.22037/uj.v20i.7393
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: Age is an established determining factor in survival in low-risk prostate cancer (PC), being this evidence weaker in high-risk tumors. Our aim is to evaluate the survival of patients with high-risk PC treated with curative intent and to identify differences across ages at diagnosis.Methods: We did a retrospective analysis of patients with high-risk PC treated with surgery (RP) or radiotherapy (RDT) excluding N+ patients. We divided patients by age groups: < 60, 60-70, and > 70 years. We performed a comparative survival analysis. A multivariate analysis adjusted for clinically relevant variables and initial treat-ment received was performed.Results: Of a total of 2383 patients, 378 met the selection criteria with a median follow-up of 8.9 years: 38 (10.1%) < 60 years, 175 (46.3%) between 60-70 years, and 165 (43.6%) >70 years. Initial treatment with surgery was predominant in the younger group (RP:63.2%, RDT:36.8%), and with radiotherapy in the older group (RP:17%, RDT:83%) (p = 0.001). In the survival analysis, significant differences were observed in overall survival, with better results for the younger group. However, these results were reversed in biochemical recurrence-free survival, with patients < 60 years presenting a higher rate of biochemical recurrence at 10 years. In the multivariate analysis, age behaved as an independent risk variable only for overall survival, with a HR of 2.8 in the group >70 years (95%CI: 1.22-6.5; p = 0.015).Conclusion: In our series, age appeared to be an independent prognostic factor for overall survival, with no differ-ences in the rest of the survival rates.
引用
收藏
页码:215 / 221
页数:7
相关论文
共 50 条
  • [31] Impact of Age and Comorbidities on Long-term Survival of Patients with High-risk Prostate Cancer Treated with Radical Prostatectomy: A Multi-institutional Competing-risks Analysis
    Briganti, Alberto
    Spahn, Martin
    Joniau, Steven
    Gontero, Paolo
    Bianchi, Marco
    Kneitz, Burkhard
    Chun, Felix K. H.
    Sun, Maxine
    Graefen, Markus
    Abdollah, Firas
    Marchioro, Giansilvio
    Frohenberg, Detlef
    Giona, Simone
    Frea, Bruno
    Karakiewicz, Pierre I.
    Montorsi, Francesco
    Van Poppel, Hein
    Karnes, R. Jeffrey
    EUROPEAN UROLOGY, 2013, 63 (04) : 693 - 701
  • [32] The multi-disciplinary management of high-risk prostate cancer
    Picard, Jonathan C.
    Golshayan, Ali-Reza
    Marshall, David T.
    Opfermann, Krisha J.
    Keane, Thomas E.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2012, 30 (01) : 3 - 15
  • [33] Current and emerging therapies for localized high-risk prostate cancer
    Moris, Lisa
    Devos, Gaetan
    Van den Broeck, Thomas
    Milonas, Daimantas
    Albersen, Maarten
    Berghen, Charlien
    De Meerleer, Gert
    Devlies, Wout
    Everaerts, Wouter
    Gevaert, Thomas
    Van Poppel, Hendrik
    Claessens, Frank
    Joniau, Steven
    EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (03) : 267 - 282
  • [34] A Review on the Current Treatment Paradigm in High-Risk Prostate Cancer
    Burgess, Laura
    Roy, Soumyajit
    Morgan, Scott
    Malone, Shawn
    CANCERS, 2021, 13 (17)
  • [35] What Are the Outcomes of Radical Prostatectomy for High-risk Prostate Cancer?
    Loeb, Stacy
    Schaeffer, Edward M.
    Trock, Bruce J.
    Epstein, Jonathan I.
    Humphreys, Elizabeth B.
    Walsh, Patrick C.
    UROLOGY, 2010, 76 (03) : 710 - 714
  • [36] Validation of a subclassification for high-risk prostate cancer in a prospective cohort
    Butler, Santino S.
    Dee, Edward C.
    Lamba, Nayan
    Sha, Sybil T.
    Mahal, Brandon A.
    Whitbeck, Amanda
    Makkar, Rishi
    Wangoe, Janet
    Mouw, Kent W.
    Nguyen, Paul L.
    Muralidhar, Vinayak
    CANCER, 2020, 126 (10) : 2132 - 2138
  • [37] Radical Prostatectomy as Primary Treatment of High-risk Prostate Cancer
    Alexandre Ingels
    Alexandre de la Taille
    Guillaume Ploussard
    Current Urology Reports, 2012, 13 : 179 - 186
  • [38] Multimodal approaches to high-risk prostate cancer
    Koupparis, A.
    Gleave, M. E.
    CURRENT ONCOLOGY, 2010, 17 : S33 - S37
  • [39] Androgen Deprivation Therapy: A Survival Benefit or Detriment in Men With High-Risk Prostate Cancer?
    Fang, L. Christine
    Merrick, Gregory S.
    Wallner, Kent E.
    ONCOLOGY-NEW YORK, 2010, 24 (09): : 790 - 797
  • [40] Optimal Treatment for High-Risk Prostate Cancer
    Ong, Wee Loon
    Koh, Tze Lui
    Millar, Jeremy
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2018, 320 (04): : 404 - 405